RICHMOND, Va., May 23, 2024 /PRNewswire/ -- Indivior PLC
(LSE: INDV; Nasdaq: INDV), a leading addiction treatment company,
announced that in anticipation of the expected primary listing
of the Company's shares on Nasdaq , members of Indivior's senior
leadership team will be hosting an analyst teach-in event today in
New York City. The event, which
will be webcast (see details below), is intended to provide an
in-depth overview of Indivior's growth and value creation path.
During the event, the Company will reconfirm its unchanged FY 2024
guidance as set forth below.
|
FY
2024
|
Net Revenue
(NR)1
|
$1,240m to
$1,330m
(+18% at midpoint
vs. FY 2023)
|
SUBLOCADE
NR
|
$820m to
$880m
(+35% at midpoint
vs. FY 2023)
|
OPVEE®
NR
|
$15m to
$25m1
|
PERSERIS
NR
|
$55m to $65m
(+43% at midpoint
vs. FY 2023)
|
SUBOXONE Film Market
Share
|
Assumes historic rate
of share decline in FY 2024 of 1
to 2 percentage points and the potential impact from
a fourth buprenorphine/naloxone sublingual film
generic in the U.S. market
|
Adjusted Gross
Margin
|
Low to mid-80s
range
|
Adjusted
SG&A
|
($575m) to
($590m)
|
R&D
|
($120m) to
($130m)
|
Adjusted Operating
Profit
|
$330m to
$380m
|
1. The OPVEE NR guidance for FY 2024 includes approximately
$8m as part of a multi-year agreement
with the U.S. Biomedical Advancement Research and Development
Authority (BARDA).
Link to today's analyst teach-in event
Webinar Registration - Zoom
About Indivior
Indivior is a global pharmaceutical
company working to help change patients' lives by developing
medicines to treat substance use disorders (SUD) and serious mental
illnesses. Our vision is that all patients around the world will
have access to evidence-based treatment for the chronic conditions
and co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD,
including alcohol use disorder and cannabis use disorder.
Headquartered in the United States
in Richmond, VA, Indivior employs
over 1,100 individuals globally and its portfolio of products is
available in 37 countries worldwide.
Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by visiting www.linkedin.com/
company/indivior.
Important Cautionary Note Regarding Forward-Looking
Statements
This announcement contains certain statements that are
forward-looking. Forward-looking statements include, among other
things, statements regarding: the Indivior Group's financial
guidance including operating and profit margins for 2024 and its
medium- and long-term growth outlook; assumptions regarding
expected changes in share and expectations regarding the extent and
impact of competition; assumptions regarding future exchange rates;
strategic priorities, strategies for value creation, and
operational goals; expected future growth and expectations for
sales levels for particular products, and expectations regarding
the future impact of factors that have affected sales in the past;
expected growth rates, growing normalization of medically assisted
treatment for opioid use disorder, and expanded access to
treatment; our product development pipeline and potential future
products, expectations regarding regulatory approval of such
product candidates, the timing of such approvals, and the timing of
commercial launch of such products or product candidates, and
eventual annual revenues of such future products; expectations
regarding future production at the Group's Raleigh, North Carolina manufacturing
facility; our intention to seek shareholder approval in
May 2024 to facilitate a primary
listing in the U.S. while maintaining a secondary listing in the
U.K., and the expected timing and potential benefits of such
listing; and other statements containing the words "believe,"
"anticipate," "plan," "expect," "intend," "estimate," "forecast,"
"strategy," "target," "guidance," "outlook," "potential,"
"project," "priority," "may," "will," "should," "would," "could,"
"can," "outlook," "guidance," the negatives thereof, and variations
thereon and similar expressions. By their nature, forward-looking
statements involve risks and uncertainties as they relate to events
or circumstances that may or may not occur in the future.
Actual results may differ materially from those expressed or
implied in such statements because they relate to future events.
Various factors may cause differences between Indivior's
expectations and actual results, including, among others, the
material risks described in the most recent Indivior PLC Annual
Report and in subsequent releases; the substantial litigation and
ongoing investigations to which we are or may become a party; our
reliance on third parties to manufacture commercial supplies of
most of our products, conduct our clinical trials and at times to
collaborate on products in our pipeline; our ability to comply with
legal and regulatory settlements, healthcare laws and regulations,
requirements imposed by regulatory agencies and payment and
reporting obligations under government pricing programs; risks
related to the manufacture and distribution of our products, most
of which contain controlled substances; market acceptance of our
products as well as our ability to commercialize our products and
compete with other market participants; competition; the
uncertainties related to the development of new products, including
through acquisitions, and the related regulatory approval process;
our dependence on third-party payors for the reimbursement of our
products and the increasing focus on pricing and competition in our
industry; unintended side effects caused by the clinical study or
commercial use of our products; our ability to successfully execute
acquisitions, partnerships, joint ventures, dispositions or other
strategic acquisitions; our ability to protect our intellectual
property rights and the substantial cost of litigation or other
proceedings related to intellectual property rights; the risks
related to product liability claims or product recalls; the
significant amount of laws and regulations that we are subject to,
including due to the international nature of our business;
macroeconomic trends and other global developments such as armed
conflicts and pandemics; the terms of our debt instruments, changes
in our credit ratings and our ability to service our indebtedness
and other obligations as they come due; changes in applicable tax
rate or tax rules, regulations or interpretations and our ability
to realize our deferred tax assets; and volatility in our share
price due to factors unrelated to our operating performance or that
may result from the potential move of our primary listing to the
U.S.
Forward-looking statements speak only as of the date that they
are made and should be regarded solely as our current plans,
estimates and beliefs. Except as required by law, we do not
undertake and specifically decline any obligation to update,
republish or revise forward-looking statements to reflect future
events or circumstances or to reflect the occurrences of
unanticipated events.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/indivior-to-host-analyst-teach-in-event-in-new-york-city-reconfirms-full-year-2024-guidance-302153680.html
SOURCE Indivior PLC